- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04717154
Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (INSPIRE)
Phase 2 INSPIRE Trial: Ipilimumab With Nivolumab for Molecular- Selected Patients With Castration-resistant Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Niven Mehra, PhD
- Phone Number: +31-24-3610354
- Email: niven.mehra@radboudumc.nl
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6525GA
- Radboudumc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Written informed consent.
- Histological diagnosis of adenocarcinoma of the prostate. Patients who have no histological diagnosis must be willing to undergo a biopsy to prove prostate adenocarcinoma.
- Metastatic Castration-Resistant Prostate Cancer (mCRPC), metastatic disease defined either as measurable disease by RECIST1.1 criteria or presence of bone-metastatic disease evaluable per PCWG3 criteria. For cohort 1, measurable disease is compulsory.
- An immunogenic phenotype, consisting of one of the next criteria: 1, mismatch repair deficiency and/or a high mutational burden of >7 mutations per Mb (cluster A); 2, BRCA2 inactivation or BRCAness signature (cluster B); 3, a tandem duplication signature and/or CDK12 biallelic inactivation (cluster C)
- Age ≥18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
- PSA ≥ 2 ng/ml.
- Documented willingness to use an effective means of contraception while participating in the study and for 7 months post last dose of treatment
- Documented ongoing castrate serum testosterone <50 ng/dL (<2.0 nM).
- Received prior castration by orchiectomy and/or ongoing Luteinizing Hormone-Releasing Hormone (LH-RH) agonist treatment.
Progression of disease by:
- PSA utilizing PCWG3 criteria
- Bone scan: disease progression as defined by at least 2 new lesions on bone scan.
- Soft tissue disease progression defined by modified RECIST 1.1.
- Clinical progression with worsening pain and the need for palliative radiotherapy for bone metastases.
Having a biopsiable metastatic lesion and willingness to undergo a baseline* and on treatment tumour biopsy for next-generation sequencing and biomarker analyses.
- When sufficient FFPE material is available from a biopsy in castrate-state, one may apply for a waiver for a new baseline biopsy.
Exclusion Criteria:
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Prior treatment with checkpoint immunotherapy (CTLA-4, or PD-1 and PD-L1 antagonists) for cohort 1. For cohort 2, patients may have prior treatment with monotherapy CTLA-4 or PD-1 or PD-L1.
- Surgery or chemotherapy within 4 weeks prior to trial entry / randomisation into the study. Any other therapies for prostate cancer, other than GnRH analogue therapy and osteoporosis preventing agents, are not allowed.
- Radiotherapy within 2 weeks prior to trial entry. Radiation-related side effects higher than grade 1, or above baseline.
- Participation in another interventional clinical trial and any concurrent treatment with any investigational drug within 4 weeks prior to trial entry/randomisation.
- History of seizure or any condition that may predispose to seizure including, but not limited to underlying brain injury, stroke, primary brain tumours, brain metastases, or alcoholism.
- Untreated or symptomatic brain or leptomeningeal involvement.
Inadequate organ and bone marrow function as evidenced by:
- hemoglobin <6.2 mmol/L
- Absolute neutrophil count <1.0 x 109/L
- Platelet count < 75 x 109/L
- Albumin <30 g/dL.
- AST / SGOT and/or ALT / SGPT ≥ 2.5 x ULN (≥ 5 x ULN if liver metastases present)
- Total bilirubin ≥ 1.5 x ULN (except for patient with documented Gilbert's disease)
- Serum Creatinine > 1.5 x ULN
- Any of the following cardiac criteria; a. Any clinically significant abnormalities in rhythm conduction, or morphology of a resting ECG (e.g., complete left bundle branch block, third degree heart block) c. Experience of any of the following procedures or conditions in the preceding six months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, congestive heart failure NYHA ≥ Grade2 d. Uncontrolled hypotension defined as systolic blood pressure (BP) <90mmHg and/or diastolic BP <50mmHg
- Clinically significant history of liver disease consistent with Child-Pugh Class B or C, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
- History of clinically relevant auto-immune disease (including Crohn's disease or ulcerative colitis). Any other finding giving reasonable suspicion of a disease or condition that contraindicates the use of nivolumab or ipilimumab or that may affect the interpretation of the results or renders the patients at high risk from treatment complications.
- Need for chronic corticosteroid therapy of >10 mg of prednisolone or >0.5mg of dexamethasone per day or an equivalent dose of other anti-inflammatory corticosteroid. Patients in which corticosteroids cannot be stopped prior to entering the trial are allowed a maximum of 10mg of prednisolone per day or equivalent. In the case of corticosteroid discontinuation, a 2-week (14 days) washout is required with a mandatory PSA check prior to starting the trial. If the PSA has declined compared to the value obtained prior to stopping corticosteroids, patients will not be eligible for study. Patients can only enter the study with a confirmed PSA increase.
- Malignancies other than prostate cancer within 3 years prior to trial entry / randomization, except for adequately treated basal or squamous cell skin cancer and non-muscle invasive bladder cancer.
- Active second malignancy, except basal or squamous cell skin cancer and non-muscle invasive bladder cancer. Other treated malignancies with curative intent, including colorectal cancer, may be included following PI consent.
- Unresolved clinically significant toxicity from prior therapy except for alopecia and Grade 1 peripheral neuropathy.
- Inability to comply with study and follow-up procedures.
- Patients with predominant small cell or neuroendocrine prostate cancer are not eligible.
- Patients without measurable lesion per RECIST1.1, and with a superscan on bone scintigraphy not evaluable per PCWG3 criteria, are not eligible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment arm
Combinatory regimen of nivolumab 3mg/kg and ipilimumab 1mg/kg, followed by nivolumab 480mg flat dose (Q4w) to up to one year. This regimen will be given to participants in both cohort 1 and 2. |
4 courses of 1mg/kg q3w
Other Names:
4 courses of 3mg/kg q3w, followed by maintenance flat dose (480mg, q4w, for 10 doses)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy endpoint: DCR
Time Frame: At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49
|
For patients with RECIST1.1 evaluable disease this includes a change from baseline in tumour volume as measured by PR or CR by best ORR, or an SD, all lasting longer than 6mo, and the absence of clinical disease progression. In patients without RECIST1.1 evaluable disease, disease control is defined by the absence of new measurable lesions and unequivocal PD of non-target lesions on CT scan, the absence of bone progression as defined by the PCWG3 criteria, and the absence of clinical disease progression |
At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety endpoint: adverse effects
Time Frame: At inclusion, Weeks 1, 4, 7, 10, 13, 17, 21, 25, 29, 33, 37, 41, 45, and 49, and at end of treatment (typically at one year, or earlier when treatment is stopped prematurely)
|
Percentage of Grade 3/4 and 5 treatment-related adverse effects
|
At inclusion, Weeks 1, 4, 7, 10, 13, 17, 21, 25, 29, 33, 37, 41, 45, and 49, and at end of treatment (typically at one year, or earlier when treatment is stopped prematurely)
|
Efficacy endpoint: BRR
Time Frame: BRR at Week 13, PSA at inclusion, Weeks 1, 4, 7, 10, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 and at end of treatment (typically one year, or earlier when treatment is stopped prematurely)
|
Biochemical response rate (BRR) at week 13 and maximal PSA decline according to PCWG3 criteria
|
BRR at Week 13, PSA at inclusion, Weeks 1, 4, 7, 10, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 and at end of treatment (typically one year, or earlier when treatment is stopped prematurely)
|
Efficacy endpoint: rPFS
Time Frame: At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49
|
Radiographic progression free survival per irRECIST1.1 immune-related response criteria
|
At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49
|
Efficacy endpoint: ORR
Time Frame: At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49
|
Best objective response rate (ORR) per RECIST1.1 criteria (cohort A1 only)
|
At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49
|
Efficacy endpoint: OS
Time Frame: Follow-up of 1 year following trial discontinuation (onwards from the 30-day safety follow-up visit).
|
Overall survival
|
Follow-up of 1 year following trial discontinuation (onwards from the 30-day safety follow-up visit).
|
Efficacy in the BRCA, CDK12 and MSI/hTMB subgroups
Time Frame: At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49
|
DCR, ORR, BRR, rPFS and OS per subgroup
|
At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49
|
Efficacy in the subgroup of patients with prior RT
Time Frame: At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49
|
DCR, ORR, BRR, rPFS and OS in patients with and without prior radiotherapy
|
At inclusion, Weeks 7, 17, 29, and 41, and 30 days after last dose given at week 49
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Translational endpoint: biomarkers
Time Frame: Through study completion, an average of 2 years
|
To further optimize and validate predictive and early response immunogenic signatures from biomarkers in tissue and blood, associating with an objective response and disease control (DCR) of at least 6 months.
|
Through study completion, an average of 2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Niven Mehra, PhD, Radboud University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
- Ipilimumab
Other Study ID Numbers
- MOURO048 - INSPIRE
- 2020-001240-25 (EudraCT Number)
- CA184-585 (Other Identifier: Bristol Meyers Squibb)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms, Castration-Resistant
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
Nuvation Bio Inc.WithdrawnProstate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic NeoplasmsUnited States
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Arcus Biosciences, Inc.Gilead SciencesActive, not recruitingProstatic Neoplasms, Castration-Resistant | Prostatic Cancer, Castration-Resistant | Castration Resistant Prostatic Neoplasms | Androgen-Resistant Prostatic NeoplasmsUnited States, Canada
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingProstate Cancer | Refractory Cancer | Castration Resistant Prostatic CancerUnited States
-
University of California, San FranciscoMerck Sharp & Dohme LLCCompletedMetastatic Prostate Cancer | Castration Resistant Prostatic CancerUnited States
Clinical Trials on Ipilimumab
-
Shanghai Henlius BiotechRecruitingHealthy Male VolunteersChina
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
-
Takara Bio Inc.TheradexCompletedMalignant MelanomaUnited States
-
Italian Network for Tumor Biotherapy FoundationBristol-Myers SquibbUnknown
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan
-
National Cancer Institute (NCI)RecruitingGlioblastoma | Malignant Glioma | GliosarcomaUnited States
-
Ontario Clinical Oncology Group (OCOG)Bristol-Myers SquibbActive, not recruitingMetastatic Renal Cell CarcinomaCanada, Australia
-
Gustave Roussy, Cancer Campus, Grand ParisCompleted
-
MacroGenicsCompletedMelanoma | Non Small Cell Lung CancerUnited States
-
Bristol-Myers SquibbCompletedCarcinoma, Renal CellUnited States, Italy, Brazil, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, France, Germany, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, Singapore, Spain, Switzerland, Turkey, United...